Following recent outbreaks of invasive meningococcal disease (IMD) in Canada and updates to provincial vaccination guidelines, the National Advisory Committee on Immunization (NACI) conducted a targeted review of evidence with a focus on immunization of adolescents and young adults. NACI reviewed national and international immunization recommendations for populations at high-risk of IMD, national IMD epidemiology and program-relevant considerations. Given the varied IMD epidemiology, NACI determined that recommending a pan-Canadian targeted program is currently challenging and that regional programs may be better suited to prevent IMD in population groups considered to be at high-risk of exposure. Further data is needed to ascertain contemporary risk factors for IMD (including activities and settings associated with bacterial acquisition, carriage and transmission) and estimate the true cost of meningococcal vaccine-preventable infections in Canada. To support provinces and territories in their decision-making, an outline of program-relevant elements for provincial and territorial consideration is provided.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10919448 | PMC |
http://dx.doi.org/10.14745/ccdr.v49i09a01 | DOI Listing |
Vaccine
December 2024
GSK, Emerging Markets, Santiago, Chile.
Background: Invasive meningococcal disease (IMD) is a life-threatening disease, primarily affecting infants and children. Argentina introduced routine meningococcal vaccination in infants and adolescents in 2017, with MenACWY vaccination targeting serogroups A, C, W, and Y (current National Immunization Program [cNIP]). Serogroup B, more prevalent since 2015, became predominant in children.
View Article and Find Full Text PDFNeisseria meningitidis is a common commensal bacterium of the nasopharynx that can cause invasive meningococcal disease (IMD). In comparison, N. gonorrhoeae is always a pathogen usually limited to mucosal sites.
View Article and Find Full Text PDFWe describe an outbreak of invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroup C in Fiji. We created surveillance case definitions and collected data by using standard investigation forms. Bacterial identification, antimicrobial susceptibility testing, and PCR were performed in Fiji.
View Article and Find Full Text PDFJ Pediatr Surg
December 2024
Dept. of Paediatric Surgery, Kings College Hospital, London, UK. Electronic address:
Objective: Choledochal malformation (CM) and biliary atresia (BA) are the two most important bile duct pathologies arising in infancy and childhood. The aim was to investigate for evidence of shared demographic features in a common temporo-spatial area.
Methods: Patients identified prospectively and defined as being born within metropolitan London in the period 1999-2022.
China CDC Wkly
November 2024
Hebei Provincial Center for Disease Control and Prevention Bacterial Disease Prevention and Disinfection Institute, Hebei Key Laboratory of Pathogens and Epidemiology of Infectious Diseases, Shijiazhuang City, Hebei Province, China.
What Is Already Known About This Topic?: (Nm) is a bacterial pathogen that causes meningococcal disease. Serogroups A, B, C, W, X, and Y account for the vast majority of cases. However, invasive meningococcal disease (IMD) caused by NmY is rare in China and has been reported only in Tianjin, Guangdong, Shanghai, and Hunan provinces and cities.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!